Dan Joyce
@ddjoyce_bfa
Assistant Professor - Urologic Oncologist @VUMCurology. HSR: Cost + financial toxicity. Former Mayo Clinic fellow and VUMC resident. Views are my own. RT≠E
ID: 968666493046149120
28-02-2018 01:57:43
194 Tweet
469 Takipçi
510 Takip Edilen
An important aspect of testicular cancer survivorship and QoL that is not always discussed…Excited to share our latest article published in @plosone: journals.plos.org/plosone/articl… Mike Hsieh Darshan Patel, MD DrBagrodia Jim Hotaling, M.D. Joshua Horns UCSD Urology University of Utah Urology
With a median FU up of ~5 yrs adjuvant pembro= 38% reduction in risk of death. The benefit is across subgroups (T stage etc). Subsequent therapy in 80% is relapses. The 1st +ve OS adjuvant PD1 study, making adjuvant pembro more attractive. #GU24 Toni Choueiri, MD
🚨 High-Yield Urology 2024 is Now Available! 👉 13 new/updated guideline summaries 👉 17 new RCT summaries 👉 25 new testing pearls 👉 new and updated tables throughout @uro_res @uroresidency @urologylist @_backtableuro Amer. Urol. Assn. ABU highyieldurology.com
Introducing the future of urology leadership! 🌟 Meet our dynamic team of Early Career Editors shaping the next wave of innovation in The Journal of Urology. Bogdana Schmidt MD, MPH Dan Joyce Benjamin Dropkin Anne Dudley, MD George Koch
Comparing the cost-effectiveness of surgery, radiation, and chemo for seminoma. Daniel Joyce, MD joins Ruchika Talwar Vanderbilt Urology to discuss his journey into cost-effectiveness studies, particularly in #TesticularCancer. #WatchNow on UroToday > bit.ly/430EobN
Long-term QOL of #GCT patients according to adj treatment pubmed.ncbi.nlm.nih.gov/38658465/ Crucial data informing impact of RPLND, chemo, XRT in CSI and >CSI GCT patients. Surveillance preferred option, but this can guide discussion! Sia Daneshmand, M.D. Scott Eggener Phillip Pierorazio nirm
Don't miss Spyros Basourakos at #AUA24 tomorrow at 9:30am, for poster session on "Contemporary Analysis of Oncological Outcomes of Radical Nephrectomy with Venous Thrombectomy for #RenalCellCarcinoma"
📺 Catch Dan Joyce's (Vanderbilt University Medical Center) discussion with Sarah P. Psutka MD MS (Fred Hutchinson Cancer Center) at #AUA24 on updates in #KidneyCancer research and how the treatment paradigm is changing as a result of #KEYNOTE564. 🎥 Watch Now: buff.ly/4aavQRy
Comparing the cost-effectiveness of surgery, radiation, and chemo for seminoma. Daniel Joyce, MD joins Ruchika Talwar Vanderbilt Urology to discuss his journey into cost-effectiveness studies, particularly in #TesticularCancer. #WatchNow on UroToday > bit.ly/430EobN
In this most recent month's Amer. Urol. Assn. news special issue on #AUAAdvocacy, I had the chance to author a piece with Kevin Wymer Vidit Sharma and Dan Joyce on implementing cost-effectiveness into clinical practice guidelines to lower patient cost of care... (1/2)
Really impactful work from YUO Michigan Urology U-M IHPI co-fellow Arnav Srivastava!
Advanced #ProstateCancer: Understanding out-of-pocket medication costs. Daniel Joyce, MD, MS joins Ruchika Talwar Vanderbilt Urology in this important discussion on the financial impact of advanced #PCa treatments on patients. #WatchNow on UroToday > bit.ly/3ADoASf
The Vanderbilt University Ingram Cancer Center Genitourinary team is expanding. We are seeking a GU medical oncology clinical investigator to join our innovative team. Please message me or Brian Rini, MD to inquire further. We will also be at #ESMO24